Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis

Hye Ryun Kim, Byung Soh Min, Jin Soo Kim, Sang Joon Shin, Joong Bae Ahn, Jae Kyung Rho, Nam Kyu Kim, Sun Young Rha

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. Results: Median overall survival (OS) was 62.8 months [95% confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95% CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5%, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. Conclusions: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalOncology
Volume81
Issue number3-4
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

oxaliplatin
Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Survival
Recurrence
Adjuvant Chemotherapy
Liver
Confidence Intervals
Leucovorin
Fluorouracil
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Hye Ryun ; Min, Byung Soh ; Kim, Jin Soo ; Shin, Sang Joon ; Ahn, Joong Bae ; Rho, Jae Kyung ; Kim, Nam Kyu ; Rha, Sun Young. / Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. In: Oncology. 2011 ; Vol. 81, No. 3-4. pp. 175-183.
@article{7048c9de8c3e46bdbd39f4ab49e09548,
title = "Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis",
abstract = "Objectives: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. Results: Median overall survival (OS) was 62.8 months [95{\%} confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95{\%} CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5{\%}, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. Conclusions: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin.",
author = "Kim, {Hye Ryun} and Min, {Byung Soh} and Kim, {Jin Soo} and Shin, {Sang Joon} and Ahn, {Joong Bae} and Rho, {Jae Kyung} and Kim, {Nam Kyu} and Rha, {Sun Young}",
year = "2011",
month = "12",
day = "1",
doi = "10.1159/000333440",
language = "English",
volume = "81",
pages = "175--183",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3-4",

}

Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. / Kim, Hye Ryun; Min, Byung Soh; Kim, Jin Soo; Shin, Sang Joon; Ahn, Joong Bae; Rho, Jae Kyung; Kim, Nam Kyu; Rha, Sun Young.

In: Oncology, Vol. 81, No. 3-4, 01.12.2011, p. 175-183.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis

AU - Kim, Hye Ryun

AU - Min, Byung Soh

AU - Kim, Jin Soo

AU - Shin, Sang Joon

AU - Ahn, Joong Bae

AU - Rho, Jae Kyung

AU - Kim, Nam Kyu

AU - Rha, Sun Young

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objectives: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. Results: Median overall survival (OS) was 62.8 months [95% confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95% CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5%, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. Conclusions: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin.

AB - Objectives: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. Methods: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. Results: Median overall survival (OS) was 62.8 months [95% confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95% CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5%, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. Conclusions: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin.

UR - http://www.scopus.com/inward/record.url?scp=80155135617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155135617&partnerID=8YFLogxK

U2 - 10.1159/000333440

DO - 10.1159/000333440

M3 - Article

C2 - 22057187

AN - SCOPUS:80155135617

VL - 81

SP - 175

EP - 183

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -